BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP
Target Group Inc. CBDY
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.9M
▼ 41.1% vs FY2024
EPS · FY25
$-0.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-35.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.9M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 35 cents on every revenue dollar this year.
Per share
USD -0.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-35.0%
Net margin-35.0%
Return on assets-19.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+164.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+164.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.62B
Shares outstanding, FY2025
Change, 5 years+7.6%
Change, 10 years—
The share count grew 8% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.2M
total assets, end of FY2025
Total assetsUSD 6.2M
EquityUSD -8.1M
CashUSD 108,800.00
Gross debtUSD 15.2M
Net debtUSD 15.1M
Current ratio0.17×
Net debt stands at -187% of equity.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.00
0.00
−0.00
−0.01
0.00
−0.01
−0.03
−0.04
−0.72
−85.83
−0.34
−0.03
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
−5282.9
−290.7
−296.5
·
·
·
·
Shares out B
0.62
0.62
0.62
0.62
0.62
0.57
0.57
0.09
0.01
0.00
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
42 of 42
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed